Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (2278)	3/2/2009 4:01:36 PM
From: dr.praveen	Read Replies (1) \| Respond to of 3661

Are u listing the whole of biotech sector:-(? eom

To: rkrw who wrote (2278)	7/8/2009 8:54:43 AM
From: RockyBalboa	Read Replies (1) \| Respond to of 3661

ARYX -55% to 1.92 on miss. ARYx blood clot treatment fails in study ARYx Therapeutics' blood clot treatment fails to meet treatment goal in late-stage study On Wednesday July 8, 2009, 7:25 am EDT Buzz up! Print Companies:Aryx therapeutics, inc. FREMONT, Calif. (AP) -- Biotechnology company ARYx Therapeutics Inc. said Wednesday the experimental anticoagulant tecarfarin failed to meet its key treatment goal in a late-stage study. The study involved 612 patients with a range of conditions including a history of blood clots, abnormal heart rhythm, and heart attacks. The aim of the study was for tecarfarin to work more effectively than the anticoagulant warfarin. The company said its drug candidate failed to meet the goal, in part, because warfarin performed better than expected. "The result for the warfarin group was unexpected based upon the extensive history of prior studies and published literature for the drug," the company said, in a statement. The company said it will fully analyze the study data before continuing ongoing partnership discussions with several large pharmaceutical companies to determine the future development of tecarfarin. Shares of ARYx fell 53 cents, or 12.6 percent, to $3.68 in premarket trading.

To: rkrw who wrote (2278)	7/27/2010 2:33:58 PM
From: tuck	Read Replies (2) \| Respond to of 3661

Momenta (MNTA) off 15% now. Not sure if it's the lawsuit filed by Sanofi -- which failed to get a TRO, and doesn't stand a snowball's chance in hell of succeeding -- or if some remark made today by Teva management actually got investors believing there is a risk that Teva's version of generic enoxaprin would be approved soon. The latter is somewhat more plausible, but still unlikely. The filing of the immunogenicity data by Teva was long ago (according to Marth a month after Momenta's), so that isn't the likely reason Teva's application hasn't been approved. I think this is a legitimate buying opportunity here. I sold my options yesterday, and sold a little in my IRA, was well. I bought back the former at $22.30, and sold puts on my trading account earlier this morning (PDT). So putting my money where my mouth is. Cheers, Tuck